126 related articles for article (PubMed ID: 10364191)
1. Potent and stable attenuation of live-HIV-1 by gain of a proteolysis-resistant inhibitor of NF-kappaB (IkappaB-alphaS32/36A) and the implications for vaccine development.
Quinto I; Mallardo M; Baldassarre F; Scala G; Englund G; Jeang KT
J Biol Chem; 1999 Jun; 274(25):17567-72. PubMed ID: 10364191
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of HIV-1 replication in primary human monocytes by the IkappaB-alphaS32/36A repressor of NF-kappaB.
Palmieri C; Trimboli F; Puca A; Fiume G; Scala G; Quinto I
Retrovirology; 2004 Dec; 1():45. PubMed ID: 15613239
[TBL] [Abstract][Full Text] [Related]
3. High attenuation and immunogenicity of a simian immunodeficiency virus expressing a proteolysis-resistant inhibitor of NF-kappaB.
Quinto I; Puca A; Greenhouse J; Silvera P; Yalley-Ogunro J; Lewis MG; Palmieri C; Trimboli F; Byrum R; Adelsberger J; Venzon D; Chen X; Scala G
J Biol Chem; 2004 Jan; 279(3):1720-8. PubMed ID: 14593121
[TBL] [Abstract][Full Text] [Related]
4. IkappaB-alpha represses the transcriptional activity of the HIV-1 Tat transactivator by promoting its nuclear export.
Puca A; Fiume G; Palmieri C; Trimboli F; Olimpico F; Scala G; Quinto I
J Biol Chem; 2007 Dec; 282(51):37146-57. PubMed ID: 17942396
[TBL] [Abstract][Full Text] [Related]
5. Distinct domains of IkappaB-alpha inhibit human immunodeficiency virus type 1 replication through NF-kappaB and Rev.
Wu BY; Woffendin C; MacLachlan I; Nabel GJ
J Virol; 1997 Apr; 71(4):3161-7. PubMed ID: 9060679
[TBL] [Abstract][Full Text] [Related]
6. Inducible expression of IkappaBalpha repressor mutants interferes with NF-kappaB activity and HIV-1 replication in Jurkat T cells.
Kwon H; Pelletier N; DeLuca C; Genin P; Cisternas S; Lin R; Wainberg MA; Hiscott J
J Biol Chem; 1998 Mar; 273(13):7431-40. PubMed ID: 9516441
[TBL] [Abstract][Full Text] [Related]
7. Live attenuated HIV vaccines: pitfalls and prospects.
Whitney JB; Ruprecht RM
Curr Opin Infect Dis; 2004 Feb; 17(1):17-26. PubMed ID: 15090885
[TBL] [Abstract][Full Text] [Related]
8. A novel chimeric Rev, Tat, and Nef (Retanef) antigen as a component of an SIV/HIV vaccine.
Hel Z; Johnson JM; Tryniszewska E; Tsai WP; Harrod R; Fullen J; Tartaglia J; Franchini G
Vaccine; 2002 Aug; 20(25-26):3171-86. PubMed ID: 12163269
[TBL] [Abstract][Full Text] [Related]
9. Transdominant mutants of I kappa B alpha block Tat-tumor necrosis factor synergistic activation of human immunodeficiency virus type 1 gene expression and virus multiplication.
Beauparlant P; Kwon H; Clarke M; Lin R; Sonenberg N; Wainberg M; Hiscott J
J Virol; 1996 Sep; 70(9):5777-85. PubMed ID: 8709193
[TBL] [Abstract][Full Text] [Related]
10. Live attenuated AIDS viruses as vaccines: promise or peril?
Ruprecht RM
Immunol Rev; 1999 Aug; 170():135-49. PubMed ID: 10566148
[TBL] [Abstract][Full Text] [Related]
11. An attenuated vaccine for AIDS?
Beale J
Lancet; 1995 May; 345(8961):1318-9. PubMed ID: 7752750
[TBL] [Abstract][Full Text] [Related]
12. A candidate live inactivatable attenuated vaccine for AIDS.
Chakrabarti BK; Maitra RK; Ma XZ; Kestler HW
Proc Natl Acad Sci U S A; 1996 Sep; 93(18):9810-5. PubMed ID: 8790413
[TBL] [Abstract][Full Text] [Related]
13. Exogenous Nef protein activates NF-kappa B, AP-1, and c-Jun N-terminal kinase and stimulates HIV transcription in promonocytic cells. Role in AIDS pathogenesis.
Varin A; Manna SK; Quivy V; Decrion AZ; Van Lint C; Herbein G; Aggarwal BB
J Biol Chem; 2003 Jan; 278(4):2219-27. PubMed ID: 12419805
[TBL] [Abstract][Full Text] [Related]
14. Gene-mutated HIV-1/SIV chimeric viruses as AIDS live attenuated vaccines for potential human use.
Hayami M; Igarashi T; Kuwata T; Ui M; Haga T; Ami Y; Shinohara K; Honda M
Leukemia; 1999 Apr; 13 Suppl 1():S42-7. PubMed ID: 10232364
[TBL] [Abstract][Full Text] [Related]
15. Attachment of human immunodeficiency virus-1 (HIV-1) particles bearing host-encoded B7-2 proteins leads to nuclear factor-kappa B- and nuclear factor of activated T cells-dependent activation of HIV-1 long terminal repeat transcription.
Bounou S; Dumais N; Tremblay MJ
J Biol Chem; 2001 Mar; 276(9):6359-69. PubMed ID: 11096063
[TBL] [Abstract][Full Text] [Related]
16. Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus.
Kumar A; Mukherjee S; Shen J; Buch S; Li Z; Adany I; Liu Z; Zhuge W; Piatak M; Lifson J; McClure H; Narayan O
Virology; 2002 Sep; 301(2):189-205. PubMed ID: 12359422
[TBL] [Abstract][Full Text] [Related]
17. Rapid size dependent deletion of foreign gene sequences inserted into attenuated HIV-1 upon infection in vivo: implications for vaccine development.
Brooks DG; Cohen MD; Jamieson BD; Poon B; Kitchen SG; Chow SA; Chen IS; Zack JA; Koka PS
Curr HIV Res; 2005 Oct; 3(4):377-92. PubMed ID: 16250884
[TBL] [Abstract][Full Text] [Related]
18. HIV with multiple gene deletions as a live attenuated vaccine for AIDS.
Desrosiers RC
AIDS Res Hum Retroviruses; 1992 Mar; 8(3):411-21. PubMed ID: 1571200
[TBL] [Abstract][Full Text] [Related]
19. Hiv-1 Tat can substantially enhance the capacity of NIK to induce IkappaB degradation.
Li X; Josef J; Marasco WA
Biochem Biophys Res Commun; 2001 Aug; 286(3):587-94. PubMed ID: 11511100
[TBL] [Abstract][Full Text] [Related]
20. Enhanced expression of HIV and SIV vaccine antigens in the structural gene region of live attenuated rubella viral vectors and their incorporation into virions.
Virnik K; Ni Y; Berkower I
Vaccine; 2013 Apr; 31(17):2119-25. PubMed ID: 23474312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
